Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human CD38/ADPRC 1 Nanobody (SAA0895)

Catalog #:   RHD80803 Specific References (28) DATASHEET
Host species: Alpaca
Isotype: VHH-8His-Cys-tag
Applications: ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RHD80803

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clonality

Monoclonal

Target

Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P28907

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0895

Data Image
  • SDS-PAGE
    SDS PAGE for Human CD38/ADPRC 1 Nanobody
References

CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies., PMID:39725695

CD38 as theranostic target in oncology., PMID:39501292

Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab., PMID:37527544

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network., PMID:37269857

Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation., PMID:37021820

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors., PMID:36405759

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy., PMID:36389758

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study., PMID:36215989

99mTc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of CD38 Expression., PMID:35696536

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells., PMID:35651607

Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053., PMID:34846151

A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma., PMID:34727950

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells., PMID:34539634

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study., PMID:34175021

ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation., PMID:33942140

ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053., PMID:33543326

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells., PMID:33396591

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies., PMID:32194826

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)., PMID:32013131

The transferrin receptor CD71 regulates type II CD38, revealing tight topological compartmentalization of intracellular cyclic ADP-ribose production., PMID:31434741

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells., PMID:30524421

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma., PMID:30459772

Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells., PMID:30185037

Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients., PMID:29907292

CD38 produces nicotinic acid adenosine dinucleotide phosphate in the lysosome., PMID:29632067

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo., PMID:29084989

Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels., PMID:28720704

Immuno-targeting the multifunctional CD38 using nanobody., PMID:27251573

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD38/ADPRC 1 Nanobody (SAA0895) [RHD80803]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only